Skip to main content
    P

    Puma Biotechnology Inc (PBYI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $7.34
    -0.43 (-5.53%)

    Market Cap: $401.70M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Puma Biotechnology Inc (PBYI) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Puma Biotechnology are Precision BioSciences (DTIL), PepGen (PEPG) and Immix Biopharma (IMMX). By market cap, Puma Biotechnology ranks 10th of the 13 companies on this page; Cullinan Oncology LLC (CGEM) is the largest at $667.39M.

    Peer Comparison

    PBYI's revenue growth of 1.1% is above the peer median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Puma Biotechnology (PBYI)$401.70M15.0x1.6x10.3%N/A1.1%0.00%
    Precision BioSciences Inc (DTIL)$288.76MN/A4.4x-85.6%-38.3%37272.0%0.00%
    PepGen Ltd (PEPG)$410.98MN/AN/A0.0%N/A0.0%0.00%
    Immix Biopharma Inc (IMMX)$657.09MN/AN/A0.0%-14.9%0.0%0.00%
    CytomX Therapeutics Inc (CTMX)$444.73MN/A31.0x0.0%-32.8%-71.7%0.00%
    Cullinan Oncology LLC (CGEM)$667.39MN/AN/A0.0%N/A0.0%0.00%
    Prothena Corporation plc (PRTA)$419.01MN/A7.8x-45.4%N/A-74.3%0.00%
    Sana Biotechnology Inc (SANA)$605.26MN/AN/A0.0%-46.8%0.0%0.00%
    Prelude Therapeutics Inc (PRLD)$275.32MN/A16.3x-269.7%N/A41.0%0.00%
    Phathom Pharmaceuticals Inc (PHAT)$492.63MN/A1.8x-30.2%11.4%71.1%0.00%
    Fennec Pharmaceuticals Inc (FENC)$410.25M159.5x6.8x3.0%N/A57.3%0.00%
    Fulcrum Therapeutics Inc (FULC)$287.96MN/AN/A0.0%N/A-100.0%0.00%
    Shattuck Labs Inc (STTK)$473.57MN/AN/A0.0%N/A-66.6%0.00%
    Peer median$431.87M159.5x7.3x0.0%-32.8%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Puma Biotechnology, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Precision BioSciences Inc (DTIL)
    Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States.
    DTIL competitors
    PepGen Ltd (PEPG)
    PepGen Inc., a clinical-stage biotechnology company, is focused on the development of oligonucleotide therapeutics for use in the treatment of serious...
    PEPG competitors
    Immix Biopharma Inc (IMMX)
    Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology...
    IMMX competitors
    CytomX Therapeutics Inc (CTMX)
    CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States.
    CTMX competitors
    Cullinan Oncology LLC (CGEM)
    Cullinan Management, Inc., a biopharmaceutical company, is focused on developing a line of targeted oncology and immuno-oncology therapies for cancer patients...
    CGEM competitors
    Prothena Corporation plc (PRTA)
    Prothena Corporation plc, an advanced stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases...
    PRTA competitors
    Sana Biotechnology Inc (SANA)
    Sana Biotechnology, Inc., a biotechnology company, focuses on the use of modified cells as medicines. The company is headquartered in Seattle, Washington.
    SANA competitors
    Prelude Therapeutics Inc (PRLD)
    Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized...
    PRLD competitors
    Phathom Pharmaceuticals Inc (PHAT)
    Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases.
    PHAT competitors
    Fennec Pharmaceuticals Inc (FENC)
    Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops candidate products for use in the treatment of cancer in the United States.
    FENC competitors
    Fulcrum Therapeutics Inc (FULC)
    Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products to improve the lives of patients with genetically defined...
    FULC competitors
    Shattuck Labs Inc (STTK)
    Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapies for the treatment of cancer and autoimmune diseases in the United States.
    STTK competitors

    Frequently Asked Questions About PBYI

    Who are Puma Biotechnology's main competitors?

    The companies most similar to Puma Biotechnology include Precision BioSciences (DTIL), PepGen (PEPG), Immix Biopharma (IMMX), CytomX Therapeutics (CTMX) and Cullinan Oncology LLC (CGEM), listed from the closest match.

    Who is Puma Biotechnology's biggest competitor?

    Cullinan Oncology LLC (CGEM) is the largest of the similar companies at $667.39M; Precision BioSciences (DTIL) is the closest match by business profile, size, sector and industry.

    How does PBYI stock compare with its competitors?

    PBYI's P/E is 15.0x against a peer median of 159.5x; its P/S is 1.6x against a peer median of 7.3x; its net margin is 10.3% against a peer median of 0.0%.

    Which of Puma Biotechnology's competitors pays a higher dividend?

    Puma Biotechnology pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Puma Biotechnology bigger than its competitors?

    No. Puma Biotechnology is 10th by market cap among the 13 companies on this page; the largest is Cullinan Oncology LLC (CGEM) at $667.39M.